Teva Pharmaceutical Industries Limited (TEVA)
Filed: 31 May 19, 12:15pm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)
| ISRAEL | 001-16174 | N/A | ||
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) |
5 Basel Street,
P.O. Box 3190,
Petach Tikva, Israel 4951033
(Address of principal executive offices)(Zip Code)
Michael McClellan
Executive Vice President, Chief Financial Officer
Tel:972-3-914-8171
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
| ☒ | Rule13p-1 under the Securities Exchange Act (17 CFR240.13p-1) for the reporting period from January 1 to December 31, 2018. |
Items 1.01 and 1.02 Conflict Minerals Disclosure, Exhibit
Conflict Minerals Disclosure and Report
A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and is publicly available athttps://www.tevapharm.com/files/about/corporate_governance/governance_doc/TEVA_PHARMACEUTICAL_INDUSTRIES_LTD_Form_SD_ 5.31.2019.pdf.
| Item 2.01 | Exhibits |
Listed below is the following exhibit filed as part of this report:
Exhibit 1.01 – Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | ||
(Registrant) | ||
By | /s/Michael McClellan | |
| Michael McClellan | ||
| Executive Vice President, Chief Financial Officer | ||
May 31, 2019